- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00049283
Erlotinib, Docetaxel, and Radiation Therapy in Treating Patients With Locally Advanced Head and Neck Cancer
A Phase I Study of the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, OSI-774, in Combination With Docetaxel and Radiation in Locally Advanced Squamous Cell Cancer of the Head and Neck
Study Overview
Status
Conditions
- Tongue Cancer
- Stage III Squamous Cell Carcinoma of the Hypopharynx
- Stage III Squamous Cell Carcinoma of the Larynx
- Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity
- Stage III Squamous Cell Carcinoma of the Nasopharynx
- Stage III Squamous Cell Carcinoma of the Oropharynx
- Stage III Verrucous Carcinoma of the Larynx
- Stage III Verrucous Carcinoma of the Oral Cavity
- Stage IV Squamous Cell Carcinoma of the Hypopharynx
- Stage IV Squamous Cell Carcinoma of the Nasopharynx
- Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma
- Stage IVA Squamous Cell Carcinoma of the Larynx
- Stage IVA Squamous Cell Carcinoma of the Oropharynx
- Stage IVA Verrucous Carcinoma of the Larynx
- Stage IVA Verrucous Carcinoma of the Oral Cavity
- Stage IVB Squamous Cell Carcinoma of the Larynx
- Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity
- Stage IVB Squamous Cell Carcinoma of the Oropharynx
- Stage IVB Verrucous Carcinoma of the Larynx
- Stage IVB Verrucous Carcinoma of the Oral Cavity
- Stage IVC Squamous Cell Carcinoma of the Larynx
- Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity
- Stage IVC Squamous Cell Carcinoma of the Oropharynx
- Stage IVC Verrucous Carcinoma of the Larynx
- Stage IVC Verrucous Carcinoma of the Oral Cavity
- Untreated Metastatic Squamous Neck Cancer With Occult Primary
- Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity
Detailed Description
PRIMARY OBJECTIVES:
I. Determine MTD and toxicity of combination of EGFR inhibitor (OSI-774), docetaxel, and radiation.
II. Pharmacokinetic profile of OSI-774 alone and in combination with docetaxel.
SECONDARY OBJECTIVES:
I. Determine the overall and complete response rate of this combination.
II. Determine overall, disease free, and progression free survival of this combination.
- EGFR expression and phosphorylation status
- Serum markers of angiogenic activity VEGF, sVEGFR-2, sKIT, ICAM, PDGF
- Fluorescence in situ hybridization (FISH) for EGFR, ERBB2, PDGFR-β for gene amplification
- DNA-sequencing of EGFR and ERBB2 genes from DNA extracted from pretreatment biopsy material for mutation screening
- Gene expression profiling on pre-treatment biopsy material to identify predictors of response to treatment
- Apoptosis (TUNEL assay)
- Ki67 (nuclear proliferation antigen).
OUTLINE: This is a dose-escalation study of erlotinib and docetaxel.
Patients receive oral erlotinib alone daily on weeks 1 and 2. Patients then receive oral erlotinib daily beginning on day 1 and docetaxel IV over 1 hour on day 3 of weeks 3-9. Patients also undergo radiotherapy once daily 5 days a week on weeks 3-9. Patients continue erlotinib for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients who had N2 or greater cervical lymph node involvement at baseline or have residual neck adenopathy after chemoradiotherapy undergo neck dissection 6-8 weeks after completion of chemoradiotherapy. Erlotinib is held for 1 week before planned surgery and until healing is complete.
Cohorts of 3-6 patients receive escalating doses of erlotinib and docetaxel until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.
Patients are followed every 16 weeks for 1 year after completion of erlotinib, every 24 weeks for 2 years, and then annually thereafter.
PROJECTED ACCRUAL: Approximately 30 patients will be accrued for this study.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Ohio
-
Cleveland, Ohio, United States, 44106
- Case Western Reserve University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients must have histologically or cytologically confirmed locally advanced (stage III or IV) squamous cell carcinoma of the head and neck without distant metastatic disease
- No prior chemotherapy, radiation therapy, or investigational anti-tumor drug
- Measurable disease within 4 weeks prior to registration according to the recommended RECIST response criteria
- ECOG performance status =< 2 (Karnofsky >= 60%)
- Life expectancy of greater than 12 weeks
- Absolute neutrophil count >= 1,500/ul
- Platelets >= 100,000/ul
- Hemoglobin >= 10 mg/dL
- Total bilirubin within normal institutional limits
- AST(SGOT)/ALT(SGPT) =< 5 x ULN when alkaline phosphatase is =< ULN
- Alkaline phosphatase =< 5 x ULN when AST or ALT =< ULN
- Prothrombin time within normal institutional limits
- Creatinine within normal institutional limits or creatinine clearance >= 60 mL/min/1.73 m^2 for patients with creatinine levels above institutional normal
- No clinically significant heart disease (including NYHA class III or IV heart disease, significant arrhythmias requiring medication, symptomatic coronary artery disease, myocardial infarction within the previous six months, second or third degree heart block or bundle branch block)
- Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control) prior to study entry and for the duration of study participation; men and women of childbearing potential must be willing to consent to using effective contraception while on treatment and for at least 3 months thereafter; women of childbearing potential must have a negative pregnancy test; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately
- Ability to understand and willingness to sign a written informed consent document
Exclusion Criteria:
- All histologies other than squamous cell carcinoma
- Salivary gland and paranasal sinus squamous cell carcinoma
- Patients who have had prior chemotherapy or radiotherapy
- Patients may not be receiving any other investigational agents
- Patients with known brain metastases or direct cerebral invasion by tumor should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events; patients with intracranial extension (but without cerebral involvement) may still be eligible to participate
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to OSI-774 or docetaxel, including other drugs formulated with polysorbate 80
- No pre-existing peripheral neuropathy >= grade 2
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
- Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated on this protocol
- HIV positive patients are excluded from participation
- Patients with history of any other malignancy (except squamous cell or basal cell cancer of the skin or CIS of cervix) are ineligible unless a period of 5 years has elapsed since treatment of the previous cancer and the patient has remained continuously disease free
- Patients who are felt to be poorly compliant
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment (erlotinib hydrochloride, docetaxel, and radiation)
Patients receive oral erlotinib alone daily on weeks 1 and 2. Patients then receive oral erlotinib daily beginning on day 1 and docetaxel IV over 1 hour on day 3 of weeks 3-9.
Patients also undergo radiotherapy once daily 5 days a week on weeks 3-9.
Patients continue erlotinib for up to 2 years in the absence of disease progression or unacceptable toxicity.
Patients who had N2 or greater cervical lymph node involvement at baseline or have residual neck adenopathy after chemoradiotherapy undergo neck dissection 6-8 weeks after completion of chemoradiotherapy.
Erlotinib is held for 1 week before planned surgery and until healing is complete.
|
Correlative studies
Correlative studies
Other Names:
Undergo radiotherapy
Other Names:
Given IV
Other Names:
Given orally
Other Names:
Undergo neck dissection
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
MTD defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity assessed using Common Toxicity Criteria (CTC) version 3.0 (Phase I)
Time Frame: 9 weeks
|
9 weeks
|
Pharmacokinetic profile (Phase I)
Time Frame: Pre-dose, 0.5, 1, 2, 4, 8, 12, 24 48, and 72 hours
|
Pre-dose, 0.5, 1, 2, 4, 8, 12, 24 48, and 72 hours
|
Time to disease progression (TTP) (Phase II)
Time Frame: Up to 5.5 years
|
Up to 5.5 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression-free survival (PFS) (Phase II)
Time Frame: From the date of treatment to date of death or date of disease progression, and to date of last follow-up for those still alive and progression free, assessed up to 5.5 years
|
Will be estimated by Kaplan-Meier method.
|
From the date of treatment to date of death or date of disease progression, and to date of last follow-up for those still alive and progression free, assessed up to 5.5 years
|
Overall survival (OS) (Phase II)
Time Frame: From the date of treatment to date of death, and to date of last follow-up for those still alive, assessed up to 5.5 years
|
Will be estimated by Kaplan-Meier method.
|
From the date of treatment to date of death, and to date of last follow-up for those still alive, assessed up to 5.5 years
|
True objective response rate (Phase II)
Time Frame: Up to 5.5 years
|
Will be estimated based on the number of responses using a binomial distribution and its confidence interval will be estimated using Wilson's method.
|
Up to 5.5 years
|
Changes of EGFR expression and serum markers over time (Phase II)
Time Frame: Baseline and up to 5.5 years
|
The Wilcoxon signed rank test (the non-parametric version of paired T-test) will be used.
|
Baseline and up to 5.5 years
|
Patterns of gene expression data (Phase II)
Time Frame: Up to 5.5 years
|
Cluster analysis including hierarchical clustering, Gaussian clustering, k means clustering, will be used.
|
Up to 5.5 years
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Panayiotis (Panos) Savvides, Case Western Reserve University
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Respiratory Tract Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Neoplasms, Glandular and Epithelial
- Respiratory Tract Neoplasms
- Pharyngeal Neoplasms
- Otorhinolaryngologic Neoplasms
- Nasopharyngeal Diseases
- Pharyngeal Diseases
- Stomatognathic Diseases
- Otorhinolaryngologic Diseases
- Mouth Diseases
- Neoplastic Processes
- Neoplasm Metastasis
- Neoplasms, Squamous Cell
- Nasopharyngeal Neoplasms
- Mouth Neoplasms
- Tongue Diseases
- Head and Neck Neoplasms
- Carcinoma
- Nasopharyngeal Carcinoma
- Carcinoma, Squamous Cell
- Squamous Cell Carcinoma of Head and Neck
- Neoplasms, Unknown Primary
- Oropharyngeal Neoplasms
- Laryngeal Neoplasms
- Laryngeal Diseases
- Carcinoma, Verrucous
- Tongue Neoplasms
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Protein Kinase Inhibitors
- Docetaxel
- Erlotinib Hydrochloride
Other Study ID Numbers
- NCI-2012-03113
- U01CA099168 (U.S. NIH Grant/Contract)
- U01CA062502 (U.S. NIH Grant/Contract)
- CWRU 1301
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Tongue Cancer
-
Indiana UniversityWithdrawnTongue Cancer | Tongue TumorUnited States
-
Fuda Cancer Hospital, GuangzhouShenzhen Hank Bioengineering InstituteCompletedRecurrent Tongue CancerChina
-
Samsung Medical CenterNational Cancer Center, Korea; Asan Medical Center; Seoul National University... and other collaboratorsRecruitingSurgery | Tongue Cancer | Squamous Cell Carcinoma | Resection Margin | Tongue Cancer TNM Staging Primary Tumor (T) T1 | Tongue Cancer TNM Staging Primary Tumor (T) T2Korea, Republic of
-
University of MichiganRecruitingOral Cancer | Tongue Cancer | Tongue NeoplasmsUnited States
-
tiejun ZhangUnknown
-
Oslo University HospitalOslo Metropolitan UniversityCompleted
-
National Taiwan University HospitalNot yet recruiting
-
Centre Hospitalier Universitaire DijonCompleted
-
Tata Memorial HospitalNATIONAL CANCER GRIDRecruitingCancer of the Head and Neck | Cancer of Mouth | Cancer of the Tongue | Buccal Mucosa Cancer | Floor of Mouth CarcinomaIndia
-
Sunnybrook Health Sciences CentreUniversity of Toronto; Sunnybrook Research InstituteRecruiting
Clinical Trials on laboratory biomarker analysis
-
Children's Oncology GroupNational Cancer Institute (NCI)Completed
-
ECOG-ACRIN Cancer Research GroupNational Cancer Institute (NCI)CompletedProstate Cancer
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Active, not recruitingLeukemia | Acute Lymphoblastic Leukemia | Acute Promyelocytic LeukemiaUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedUntreated Adult Acute Lymphoblastic Leukemia | Untreated Childhood Acute Lymphoblastic LeukemiaUnited States, Canada, Australia, New Zealand, Puerto Rico, Switzerland
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedChildhood Acute Lymphoblastic Leukemia in Remission | Recurrent Childhood Acute Lymphoblastic LeukemiaUnited States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)CompletedLung CancerUnited States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Completed
-
Children's Oncology GroupNational Cancer Institute (NCI)WithdrawnClear Cell Renal Cell Carcinoma | Rhabdoid Tumor of the Kidney | Congenital Mesoblastic Nephroma | Childhood Kidney NeoplasmUnited States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)WithdrawnBreast Carcinoma | BRCA1 Mutation Carrier | BRCA2 Mutation CarrierUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedWilms Tumor and Other Childhood Kidney TumorsUnited States